NuPathe Company Profile (NASDAQ:PATH)

About NuPathe (NASDAQ:PATH)

NuPathe logoNuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PATH
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.14
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
Frequently Asked Questions for NuPathe (NASDAQ:PATH)

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Who are some of NuPathe's key competitors?

How do I buy NuPathe stock?

Shares of NuPathe can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuPathe's stock price today?

One share of NuPathe stock can currently be purchased for approximately $4.25.

MarketBeat Community Rating for NuPathe (NASDAQ PATH)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NuPathe (NASDAQ:PATH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NuPathe (NASDAQ:PATH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushDowngradeOutperform -> Neutral$8.00 -> $5.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for NuPathe (NASDAQ:PATH)
Earnings by Quarter for NuPathe (NASDAQ:PATH)
Earnings History by Quarter for NuPathe (NASDAQ PATH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2013Q3($0.20)($0.25)ViewListenView Earnings Details
8/8/2013Q2 2013($0.20)($0.16)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.17)($0.68)ViewN/AView Earnings Details
3/26/2013Q4 2012($0.33)($1.16)ViewN/AView Earnings Details
11/12/2012Q312($0.38)($0.42)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NuPathe (NASDAQ:PATH)
Current Year EPS Consensus Estimate: $-1.26 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS


Dividend History for NuPathe (NASDAQ:PATH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NuPathe (NASDAQ:PATH)
No insider trades for this company have been tracked by


Headline Trends for NuPathe (NASDAQ:PATH)
Latest Headlines for NuPathe (NASDAQ:PATH)



NuPathe (PATH) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff